99mTc标记单域抗体用于SPECT/CT评估多种癌症类型HER2表达
研究纳入6例HER2阳性、经多线治疗的不同癌症类型患者(年龄42至69岁,5女1男,中位年龄55.5),共7次扫描,其中1例间隔3个月扫描两次;注射RAD201(434±42 MBq)前给予Gelofusine®溶液500 ml(40 mg/ml)用于辐射防护;结果显示RAD201在患者体内分布与既往研究(NCT04040686)一致,应用血浆扩容剂Gelofusine®可使关键器官肾脏的辐射剂量降低近50%;结论认为RAD201在人体中似乎安全,是有希望的无创鉴别转移性(乳腺)癌HER2状态的工具,不论是否正在接受HER2靶向抗体治疗。
要点
- 6例HER2阳性经多线治疗的不同癌症患者共行7次RAD201扫描,1例间隔3个月两次扫描。
- 注射RAD201(434±42 MBq)前给予Gelofusine®溶液500 ml(40 mg/ml)可使肾脏辐射剂量降低近50%。
- RAD201在患者体内分布与既往研究(NCT04040686)一致,似乎安全,可用于无创鉴别HER2状态。
核心结论
- RAD201在人体中似乎安全,是有希望的无创鉴别转移性(乳腺)癌HER2状态的工具,不论是否正在接受HER2靶向抗体治疗。
研究设计与样本
- 共纳入6例HER2阳性、经多线治疗的不同癌症类型患者,年龄42至69岁(5女1男,中位年龄55.5),共行7次扫描,其中1例间隔3个月扫描两次。
- 7次扫描中6次在注射示踪剂前给予Gelofusine®溶液500 ml(40 mg/ml)用于辐射防护,示踪剂注射活度为434±42 MBq。
- 注射后10分钟、60分钟、160分钟、20小时和24小时行平面扫描,95分钟行CT扫描后行局部SPECT断层成像。
主要发现
- RAD201在患者组中的体内分布与既往RAD201研究(NCT04040686)一致。
- 应用血浆扩容剂Gelofusine®可使关键器官肾脏的辐射剂量降低近50%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The expression status of human epidermal growth factor receptor 2 (HER2) in cancer predicts response to HER2-targeted therapy. Therefore, its accurate determination is of utmost importance. In recent years, there has been an increase in research on noninvasive techniques for molecular imaging, as this method offers the advantages of a more accurate determination of HER2 status without the need for multiple biopsies. The technetium-labeled single-domain antibody RAD201, previously known as 99mTc-NM-02, has been shown to be safe for use in breast cancer imaging with reasonable radiation doses, favorable biodistribution, and imaging characteristics. METHODS: A total of six HER2-positive, heavily pretreated patients with different cancer types aged between 42 and 69 years (5 women and 1 man; the median age of 55.5) have been examined. In six of seven scans, the patients were administered 500 ml of Gelofusine® solution (40 mg/ml) for radiation protection before the tracer injection (434 ± 42 MBq). Planar scans were acquired with the patient supine at 10 min, 60 min, 160 min, 20 h, and 24 h after injection. A CT scan was acquired at 95 min, followed by local tomographic SPECT imaging. RESULTS: One patient was scanned twice with RAD201, 3 months apart, resulting in a total of seven scans for six patients. Here, we show that the use of RAD201 in our patient group shows the same favorable biodistribution as in a previous study with RAD201 (NCT04040686) and that the radiation dose to the critical organ kidney can be reduced by the application of the plasma expander Gelofusine® by almost 50%. CONCLUSION: RAD201 appears safe for use in humans and is a promising noninvasive tool for discriminating HER2 status in metastatic (breast) cancer, regardless of ongoing HER2-targeted antibody treatment.
引用
- Altunay B, Goedicke A, Winz OH, et al. 99mTc‑labeled single-domain antibody for SPECT/CT assessment of HER2 expression in diverse cancer types. Eur J Nucl Med Mol Imaging. 2022. PMID: 36482076. doi:10.1007/s00259-022-06066-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。